Lumexa Imaging Holdings, Inc. (LMRI) Earnings Call Transcript
August 12, 2026
Earnings Call Speaker Segments
Thanks so much, and good day to all of you; we're glad you could be with us. Caitlin Zulla, our Chief Executive Officer, and Tony Martin, our Chief Financial Officer, are heading up the call today. Before we get started, I'd like to point out that during this discussion we'll be making forward-looking statements, among them statements about our 2026 guidance, anticipated operating performance, growth initiatives, reimbursement assumptions, capital expenditures and other upcoming events. Those statements represent our present expectations and assumptions, and they carry risks and uncertainties that might lead actual results to differ materially. For more details, please see the forward-looking statements and risk factors laid out in today's earnings release and in our most recent SEC filings; we assume no duty to update these statements. We'll also be covering certain non-GAAP financial measures. Today's earnings release contains definitions along with reconciliations to the most directly comparable GAAP measures. With all that said, I'll hand things over now to Caitlin. Please go ahead, Caitlin.
Thanks, Sue, and welcome everyone to today’s call. During the second quarter, we made considerable headway as we kept carrying out the strategic priorities that underpin our goal of creating the leading platform for outpatient imaging that is both high-quality and lower-cost, serving health systems, physicians, and patients. Those priorities involve generating robust growth at existing centers with a richer blend of advanced modalities, launching new de novo sites and making sure newly opened centers ramp successfully, speeding up high-impact strategic service lines, and widening our geographic reach through growth that is disciplined and efficient in its use of capital. I’m excited to walk you through what we accomplished tonight. Here are several highlights from the quarter. During the second quarter, our core business once again demonstrated its durability. We achieved meaningful growth in overall same-center volumes, maintained our forward drive in advanced modalities, watched our de novo groups keep maturing, and made significant progress in expanding relationships with health systems. Advanced modalities climbed to 37.4% of overall volume — a record level for our organization and 111 basis points higher than the prior-year figure. Our continued move toward a richer advanced modality mix keeps gaining steam, driving better reimbursement and margin for the company; in May, we unveiled four additional centers. So far in 2025, we've launched two de novos, while our ongoing goal remains 8 to 10 annually; we've also completed two acquisitions, including the first location under our UPMC joint venture. As previously mentioned, the rest of this year's openings will happen later, and we remain on track to hit our full-year de novo target. In June, we hit a significant milestone: a joint venture with Hospital for Special Surgery, a worldwide leader in musculoskeletal health, expanding our footprint in the New York City metro area. Over the course of this quarter, we've been busy bringing new de novo sites up to speed. Both our 2024 and 2025 groups are delivering results right in line with our expectations — they're contributing a solid blend of advanced procedure volumes, and we're making real headway on the goals we've set for expanding both growth and profitability over the long term. Those wins leave us well positioned as we move into the back half of the year. Between what we achieved in Q2 and the momentum building across our main growth programs, we feel good about hitting our full-year targets, including the revised guidance we're sharing today. Tony will walk you through the details in a moment. And our mission still drives us every day: opening up more access to top-quality imaging at a lower cost, delivered with ever-greater compassion. The effort our team is putting in, and the enthusiasm they show for what they do at Lumexa day in and day out, makes me very proud. We just wrapped up the yearly survey on employee engagement, and the results were the best we've ever had — which says a lot about a group that shares a common focus and draws motivation from our goal of becoming the top choice for premier radiologists and health systems. Growing as we do rests on that engaged spirit and sense of common mission. When it comes to the opportunity in our market, we're still at the beginning, but even so, what we offer clearly strikes a chord with patients, providers, health systems, and payors. Through either centers we own entirely or ones operated as joint ventures, we're succeeding at providing top-notch imaging in places that are easier to reach, done faster, and costing significantly less than what hospital outpatient departments charge. We've assisted health systems in tackling key operational difficulties and in reaching their objectives for patient care and market growth; plus, patients are fond of the care they get, something our Net Promoter Scores show, as they regularly go beyond 90. Indeed, an article was just put out by Kaufman Hall called Radiology strategy was never about radiology, and it says, Imaging is not simply a department. This matters enormously for how health systems expand in areas like cancer care, heart and vascular services, brain and nervous system treatment, and bone and joint medicine; our partnership on this front is as solid as it gets. When it comes to Lumexa, simply operating imaging facilities isn't the whole picture. Our role involves helping health systems improve how easily people can get care, retain those patients, and strengthen their bottom line. We look at imaging access as the gateway into a health system's single most important service category, and we've helped health systems take charge of that gateway while spending less, placing services in convenient locations for their patients, and using an operating model that creates benefits for everyone involved. As you're aware, in early July, CMS put out its proposed rule for the 2027 Hospital Outpatient Prospective Payment System; we think this proposed OPPS rule offers additional confirmation of where health care is headed. Excellent imaging ought to be provided in the setting that's most suitable and cost-efficient. Should it be finalized as suggested, the site-neutral clauses would lessen the reimbursement edge tied to hospital outpatient departments and further bolster the case for health systems to grow lower-cost freestanding imaging capacity. Lumexa is designed for this kind of setting. Our approach lets health systems boost access, grow in a strategic way, and take part in outpatient imaging expansion with a cheaper cost structure that isn't reliant on a hospital-based reimbursement premium. Though the proposal is still open to comments and finalization, we see the move toward outpatient imaging as a structural growth catalyst that will help us over years, not quarters. On other government topics, we went over CMS' proposed rule for the 2027 Medicare Physician Fee Schedule, which came out in July. Just to remind you, this ties into our present rate presumptions of roughly level government reimbursement rates from one year to the next and a 1% rise in commercial payor rates. Should the CMS rule go through in the form that's been proposed, we believe it would match the assumption we've built into our planning around government payor rates. Roughly 20% of our revenue comes from Medicare Advantage plus fee-for-service. Turning to our commercial payers, who represent the largest portion of the mix, we're fortunate that our payer set is diverse and that contracts come up for renewal in different years. And so far in 2025, what we're hearing in commercial negotiations also supports the presumptions we're using to plan ahead. Here at Lumexa, we're pursuing a market opportunity that is both substantial and growing, and that market is moving in our direction. There are lasting, long-term favorable forces at work that, in our view, are only beginning to emerge: populations getting older with conditions that are more complicated and chronic, novel therapeutic approaches that call for sophisticated imaging, increasing rates of preventive screening, plus a continuing migration of care away from hospitals toward outpatient locations within a fragmented industry where capacity is tight. One genuine standout moment from Q2 was the reveal of our ninth joint venture with a health system — a strategic alliance with Hospital for Special Surgery, a globally admired authority in musculoskeletal health. I'd like to discuss this impressive collaboration in somewhat greater depth, since we view it as considerable proof that our joint venture model works. In orthopedics, HSS holds the #1 ranking within the U.S. and is known worldwide for outstanding clinical results. Partnering with Lumexa was a choice that came after a demanding assessment of how we deliver clinically and how we operate. HSS provides a thrilling boost to our ambition of assembling a wide network of imaging centers across several of the country's most appealing markets. Picture residents of New York seeing their specialists in Manhattan and then getting prompt, easy imaging in nearby communities. The New York metro region ranks among the biggest health care markets nationwide, and we are eager to care for patients and the providers who refer them throughout this strategically important MSA. It is an honor that HSS picked Lumexa as its partner; coming after UPMC, this marks our second fresh health system tie-up within the past 12 months and demonstrates the expanding pipeline of health systems that are actively looking to broaden outpatient imaging access at their hospitals.
Actually, a recent assessment of the market uncovered a sizable group of health systems—roughly 100—in which our approach is able to serve a clear need for outpatient imaging, which gives us assurance regarding how deep and how long our pipeline of partnerships will run. The opportunity awaiting us is both encouraging and enormous, and what we provide is persuasive; beyond the longer-term market dynamics underpinning our expansion objectives, our operational and commercial groups have worked alongside clinical leaders to roll out significant initiatives that improve care and fuel growth. To be specific, our team is occupied with efforts aimed at generating growth within existing centers and broadening access carefully, with priority placed on advanced modalities. Let me elaborate a bit. PET stood out strongly during Q2, growing 23.2%. We keep pushing our approach forward in this area, installing 2 of the 3 new PET machines we were targeting in July; we are likewise moving into additional tracers, which opens up our valuable PET capabilities to a wider set of patients, among them the tracer FES, or fluoroestradiol, for patients with estrogen-positive breast cancer. Turning to DAC, our breast arterial calcification program powered by AI keeps gaining solid traction across New York and New Jersey, and we are pushing ahead with plans to extend into other regions; we recently kicked off our lung cancer screening effort; it encompasses initiatives meant to encourage patient participation in what ranks among the highest-impact screening possibilities within our patient population. Through greater awareness and better access, we can assist more patients in getting screened, receiving a diagnosis sooner and being linked to care that saves lives. In the U.S., lung cancer is still the top cause of deaths tied to cancer; and merely around 18% of those who qualify presently undergo screening, which is a glaring disparity next to the 72% screening rate seen with colorectal cancer. Focused clinical outreach campaigns such as these continue to be something our company excels at. During Q2, we kept moving forward with our capital-light, best-of-breed technology approach. As of today, we are bestowing a name upon that integrated capability: Lumexa Imaging Connect. The operating platform linking patients, referring physicians, radiologists and health system partners throughout the imaging journey is Lumexa Connect. Founded upon leading technologies, our platform enables us to bring in emerging innovations swiftly instead of needing to build each solution on our own. Lumexa Connect is central to our approach, and it has been built to help us act more quickly, bring new partners aboard smoothly, broaden access, boost capacity and scale effectively as we expand; results from this approach are already becoming visible; we are still on schedule to roll out FastScan across 2/3 of our centers before the year ends, which helps cut MRI scan times and grow capacity. We are additionally making progress on virtual MRI capabilities and introducing AI-powered dictation and reporting tools intended to boost radiologist productivity, lessen physician burnout and speed up how quickly reports are turned around. Lumexa Connect isn't some fresh strategy; it is simply the label for the scalable operating platform already powering our centers, our partners and our ongoing growth. A fresh name, yet the model remains asset-light and top-tier; moreover, we'll keep advancing this platform using the finest technologies to drive better service and operational results for patients, referring physicians, radiologists, and health system partners. On that note, let me pause briefly to spotlight one more way our company stands apart: the investments that empower our own technologists to reach their goals. I'm happy to report that during Q2, our 100th technologist completed Lumexa's Technologist Advancement Academy, covering advanced modalities alongside mammography, with participants drawn from every one of our geographies. I take pride in how our team backs this vital effort, which helps make Lumexa a wonderful place that our clinical colleagues are glad to call home. To close, I'm pleased with the progress we're making as we carry solid momentum into the year's second half. De novos are picking up pace, and advanced modalities now represent a rising share of our mix. Our JV pipeline is strong, and we're moving into significant new markets alongside outstanding health system partners. My confidence remains firm in our capacity to carry out our strategic priorities and meet our full year commitments, and I feel we've only just begun. Before handing the call to Tony, I'll take my usual quarterly moment to express enormous gratitude to our devoted team members and radiologists. Your dedication to our patients and to our mission underpins all that we do; so, Tony, please go ahead.
Thanks, Caitlin, and thanks to everyone for being on the call. This evening I'll go over the financial results and talk about what drove our performance in the quarter. After that, I'll give our outlook for the entire year. As a complement to my walkthrough of our GAAP financials, I'll cover some system-wide financial and operating metrics that offer extra perspective on how we're doing overall and on the reach of our business. These metrics are part of how we manage the business, since they capture activity at every center we run — those we own outright and those run through our joint ventures alongside health systems. Now to our second quarter financials. Consolidated revenues reached $264.2 million, up 5.1% from the equivalent period a year ago. System-wide revenue growth, which takes in every site we operate, was 6% for the quarter, fueled by robust growth in advanced modalities. Revenue per scan in our outpatient segment rose 2.2%. That's a system-wide metric we rely on because it gives helpful insight into outpatient economics by capturing both the technical scan revenue where applicable and the associated professional read revenue. The year-over-year gain came from advanced modalities making up a bigger portion of our business, along with modest upticks in contracted payor rates, partly offset by payer mix shifts in a few markets. Before diving deeper into the financials, I want to go over some important volume metrics; we saw strong system-wide volume performance at our outpatient sites in Q2, both wholly owned and in JVs. System-wide volume growth was 3.1%, with strength in advanced imaging somewhat held back by routine scans, though we did see improvement in mammography volumes, which began the year slower than expected. Routine scans affect our earnings less than advanced ones, but we were pleased to see them get better during the quarter. Advanced modality volumes, which generally get reimbursed 3x to 4x higher than routine modalities, stood out, growing 6.3% system-wide versus prior year and 6.8% on a consolidated basis. As Caitlin already pointed out, advanced modalities made up 37.4% of our volumes this quarter, an increase of 111 basis points over the prior year period. It's encouraging that these procedures have kept growing steadily and now account for a higher mix of our system-wide volumes. Now for a little more detail on our consolidated revenues. Outpatient net patient service revenues were $143.7 million, growing 3.5% on healthy same-site growth. Professional fee net patient service revenues, our second operating segment, came to $64.2 million, reflecting growth of 5%, in line with our model. Lastly, management fee and other revenues grew $7.2 million and totaled $60.4 million for the quarter. Within that management fee line, roughly $26 million mostly represents management fees we earn from operating the sites in our health system JVs, which saw particular strength this quarter. The remaining $34 million in this category represents zero-margin pass-through of employee, IT and site level costs that we pay on behalf of our joint ventures. When you're building your models for us, it's crucial to grasp how these 2 components affect margin. G&A came in at $24.4 million for the quarter, which is $5.7 million above the second quarter of 2025. We had anticipated this rise, and it stemmed from $5.9 million in higher expenses tied to the 2 primary components we discussed last quarter, and those will keep affecting year-over-year comparisons all through 2026. Here's what they are: first, our pubco costs, the ongoing expenses tied to operating as a public company. These totaled $1.5 million in the quarter, and we still expect roughly $7 million of such costs for full year 2026. Second, and likewise comparable to last quarter, is a rise in stock-based compensation, moving from $8.3 million in Q2 of '25 to $12.7 million in Q2 of '26. That mirrors the onetime resetting of legacy equity comp plans tied to our IPO; for full year 2026, we expect stock-based comp of approximately $50 million. Roughly half of that is tied to historic M&A and will be fully amortized by the close of 2026. Consequently, we foresee ongoing stock-based compensation of approximately $20 million to $28 million for full year 2027. Beneath operating expenses, we include our equity and earnings of unconsolidated affiliates; that represents our pro rata ownership share of net income from our JV sites, the line item in our financials reflecting what these important partnerships contribute. At $18.6 million, it was $2.1 million above Q2 of '25, reflecting especially strong performance this quarter at the sites we run with health system partners. Beneath the operating line, interest expense totaled $16.2 million in Q2. This new run rate sits $14 million below Q2 '25, reflecting our use of IPO proceeds to pay down debt last December, which frees up more than $50 million in cash interest expense savings on an annualized basis and boosts our flexibility to invest in growth; on top of that, we repriced our debt in June 2026, cutting our go-forward run rate for interest expense by another $1 million per quarter beginning in Q3. Pretax income reached $5.8 million for Q2 versus a pretax loss of $2.4 million in Q2 '25. Following a tax provision of about $3 million in the quarter, net income came to $2.7 million in Q2 versus a net loss of $7.2 million in the prior year period. Our GAAP EPS was $0.03 per share in Q2 and adjusted EPS was $0.20. Turning now to adjusted EBITDA, an important supplemental measure we use to evaluate operating performance across our entire network; it includes adjusted EBITDA from our wholly owned centers as well as our pro rata share from the centers we operate through our health system joint ventures. Adjusted EBITDA was $56.4 million in the quarter compared with $56.3 million a year ago. Our underlying results got a lift from solid volumes across the board and impressive expansion in advanced modalities, though reported growth had to absorb added public company costs along with planned spending tied to bringing our de novo centers up to speed. When we look at the year-over-year picture, it also reflects a prior year baseline that was tougher than what we faced in Q1, since the volume rebound that came after an out-of-network situation got settled had mostly played out by the second quarter of 2025. Adjusted EBITDA margin came in at 21.4% for Q2 '26, versus 22.4% for Q2 '25, driven in part by the $1.5 million step-up in public company costs. Looking sequentially, adjusted EBITDA margin was up 110 basis points from Q1; turning to cash flow, operating activities delivered $32.8 million during Q2 '26. That figure sits $31 million above Q2 '25, which speaks to our lower senior credit facility debt and the related interest payments. Free cash flow — which we define as cash flows from operating activities less CapEx — reached $23.1 million in Q2 '26, a record high for the company, against negative $2.5 million in Q2 '25. That works out to a $25.6 million improvement and produced a conversion in Q2 of roughly 41% of adjusted EBITDA, which is yet another record. The gain came mostly from our reduced debt and related interest expense, showing that our business can keep generating strong cash flow.
Keep in mind that we directed every dollar from the IPO toward reducing debt, which was meant to unlock cash for chasing our market opportunity, expanding the business, and bringing leverage down. One quarter shouldn't be viewed as a fresh run rate. That said, as mentioned before, we still anticipate that free cash flow conversion for 2026 will come in at roughly 25% to 30% of adjusted EBITDA when measured across the entire year. Although conversion of free cash flow may fluctuate, we think this range will strengthen as our business scales; and now a brief note on CapEx. We still see room to speed up our growth plans within our fragmented industry and to aim for meaningful returns by putting money into de novos, installing new and upgraded equipment and capabilities at sites we already operate, and pursuing targeted M&A. The $9.7 million we spent on capital in Q2 '26 represents a quarter packed with investment activity rather than any shift in our underlying spending plan. We still expect cash CapEx of roughly $5 million to $7 million each quarter. Turning to the balance sheet. Our capital position remains solid, and we closed the quarter holding $69.7 million in cash and cash equivalents, which is up from $58.8 million when the quarter began. At June 30, net leverage stood at 3.6x, versus 5.7x one year earlier. On top of that, we remain dedicated to handling our capital structure strategically. And when Q2 ended, we repriced our term loan at a rate of SOFR plus 250 basis points. That decrease produces extra annual cash interest savings totaling $4 million per year beginning in Q3. To finish with our outlook, we feel good about what we achieved in Q2, such as progress on important growth initiatives. So now that half the year is behind us, we're tightening our adjusted EBITDA guidance range to $235 million to $241 million, compared with the earlier range of $234 million to $242 million, while keeping the midpoint at $238 million. This tighter range mirrors our first half results, how we see the business, and our ongoing confidence in the underlying assumptions behind our guidance. Adjusted EBITDA captures our full system-wide footprint, including our pro rata share of JV performance, whereas our consolidated revenue guidance captures only our majority-owned centers. That difference in scope, rather than any shift in how we view either business, explains why we're tightening adjusted EBITDA guidance while our revenue guidance stays unchanged; and so tonight, we're reaffirming our consolidated revenue guidance of $1.045 billion to $1.097 billion along with our adjusted EPS guidance of $0.71 to $0.77 per share. As we head into Q3 and keep working toward our goals, the opportunities ahead of us and the progress achieved so far this year have us energized. So with that, let's get to your questions. Operator, could you please open the call?
Brett Grulkowsk here, filling in for Brian Tanquilut from Jefferies. When we look ahead to the back half of the year, could you share what you expect in terms of seasonality for the business? And also, are there any additional incremental drivers worth highlighting as we consider that sequential ramp?
Thanks a lot, Brett. I appreciate that question. Perhaps I'll start us off, and then hand things over to Tony so he can speak more about how the second half is paced; we're really enthusiastic about the progress we've shown so far this year. Advanced imaging remains robust, and I'm genuinely delighted that we hit a fresh company record, with 37.4% of volumes originating from advanced imaging; and as you may recall, we achieved a record count of de novos last year. We launched 9, and the pacing broke down as 3 during the first quarter, 3 during the second, 0 during the third, followed by 3 during the fourth. So we're excited about the momentum we've witnessed as our 2024 and 2025 de novo cohorts continue ramping. What you're seeing, then, is effectively a compounding of all those trends as we move into the back half of the year, which explains why we felt confident reaffirming our guidance and narrowing the range. But Tony, I'll let you perhaps elaborate a bit more on the specific pacing.
Absolutely, absolutely. So yes, the pace of things matched what we anticipated for how the year would play out. This business has its own inherent seasonal pattern, and that's exactly what we're observing. As we mentioned in last quarter's report, we projected that 45% of our earnings would land in the first half, with 55% coming in the back half, and we are precisely on track with that. That stems from volume building up seasonally along with our de novos ramping. We had such a large number of those open in 2025. So we're exactly where we want to be on that 45% for the first half, plus the sequential ramping we expect to keep going in Q3 and Q4; and in fact, at 45.3%, if we want to go out to a decimal point; so we're actually slightly ahead of that.
Great. Okay. Yes, that helps. As a follow-up, could you give us a bit more detail on the HSS JV that was recently announced — perhaps how things have gone in those first stages? And is there any chance to expand it down the road? Also, more generally, what does the pipeline of new JV possibilities look like overall?
Yes. Glad to discuss HSS. For our company, it marked a really thrilling milestone. HSS is, clearly, an institution known worldwide, and its focus is musculoskeletal, which, clearly, calls for imaging throughout every stage of diagnosis and treatment. With HSS, much like UPMC, our approach centers on de novo. We've already identified markets within the New York metropolitan area and are actively moving the site plan forward. New York has CON requirements, which means the time line will be somewhat longer, but we're eager to share a bit more on this as we head into 2027. Then, turning to the second part of what you asked regarding hospital engagement and the hospital pipeline: one reason I'm most thrilled to hold this role at Lumexa is how early we are in terms of chances to keep expanding to meet outpatient needs in the industry. To begin with, radiology demand keeps rising for all the reasons we've discussed, right — novel treatment paradigms, increased screening mandates, technological advances — and unmet demand persists. Beyond that, the landscape is also incredibly fragmented, and it's very early for health systems to truly start formalizing their outpatient imaging strategy; so we have an exciting pipeline of health systems we're speaking with. We look forward to providing more updates over the coming quarters. But there's plenty of growth and opportunity here. Thanks so much, Brett.
Perhaps to start, we've already heard quite a bit from various participants in this sector during the quarter or via the earnings reports. I suppose, Tony, I believe you brought up some shifts in payor mix across a few markets. Could you elaborate on that a bit further? And anything you're observing regarding procedure mix, whether that's movements in ortho-related imaging versus procedures that are more oriented toward acute care? I'd just love to hear your observations and what's underlying some of those volume changes.
Certainly. After I provide a couple of figures here, I'll have Caitlin add some color. But really, yes, we observed merely a slight shift in payor mix, nothing significant. It occurred in a couple of markets, and it differed somewhat from what we experienced in Q1. Different segments of the business went through some ebbs and flows in this area. So really nothing noteworthy or anything that would become a long-term trend, just a modest shift. And as you could see, we landed where we anticipated; so it wasn't — clearly, it wasn't significant. And Caitlin, could you take...
Absolutely, Andrew — I'm glad to speak to the acuity side of things. When we examine acuity and review our entire book of business, MRI keeps showing genuine momentum. On a system-wide basis, MRI posted growth of 7.2% quarter-over-quarter. So our emphasis stays on backing MRI, and then PET as well, which grew 23.2%, just as we pointed out in the script. All along, we've discussed what Lumexa can do to strengthen its PET presence; so it's exciting to report that 2 of the 3 machines we mentioned earlier this year are now operating in South Carolina and Arizona. On top of that, progress with radiotracers keeps coming. We brought up our new estrogen-positive breast imaging radiotracer, FES. Demand remains robust for amyloid, PYLARIFY, and we're also advancing work on Ga-68 and FDG; so PET remains a strategic service line we're focused on growing, given how strongly acuity is driving demand there.
We don't have the Q yet. I was hoping you could share the same-store system-wide revenue growth metric in the quarter and talk through the underlying components of that between volume and price. Answer from J.
Martin: Sure. The same-site volume growth, was that...
Sure, regarding system-wide revenue at stores open at least a year — what figure did we record for the quarter, and could you perhaps separate that into the price and volume elements?
Absolutely. On a same-site, system-wide basis, revenue came to 4.4%, with volume at 2.2% and rate at 2.2%.
Understood, that's useful. And regarding the commercial mix, may I go back to that briefly? I found it somewhat ambiguous what you're actually observing there. So first, could you tell us how it ended up for the quarter? How much did it decline compared with a year ago? And if you did encounter pressure in certain markets, could you explain precisely what you observed?
Certainly. Right. Once the Q is published, it will indicate a 59% consolidated commercial mix, matching what we had a year earlier. There was a tiny move lower, but nothing meaningful, correct? We've listened to some other health care providers, especially hospitals, discuss a bigger payor mix shift. That wasn't something we truly witnessed. In Q2, it involved a handful of markets where we consolidate. And during Q1, we experienced somewhat more deterioration on the JV side, and neither situation appears to signal anything lasting, as far as we can determine. And as I mentioned, it's really minor since it amounts to essentially a rounding error in our payor mix percentages.
When you look at Q1, you had certain disruptions tied to weather. Has any portion of that volume been made back during Q2 in your view? Or does it simply remain gone now?
Yes. Whit, I appreciate the question. Perhaps I'll begin; Q1 showed us the strength of advanced, and the way it finished made us quite proud. As a result, we expected almost no advanced carryover into Q2. Speaking of how advanced did in Q2, it once again delivered solid results. The effect our new facilities are exerting on the enterprise growth rate overall is visible. Mammography was among the areas we concentrated on regarding recovery. We had mentioned it was lagging as Q1 closed. It's exciting to see mammography expand this quarter. Year-over-year, mammo is higher by 2.6%, and it keeps rising beyond 6% per day compared with Q1. Thus, mammo is the single area where we noticed some opportunity as well as pull-through. Once more, our emphasis is on advanced since its reimbursement rate is much greater than routine's, yet seeing the mammo book bounce back is good.
All right. I was wondering whether there's any expense you'd want to identify in connection with the data breach?
Yeah. Thank you, Whit. Regarding the data breach, we put out information about it during our Q1, first so it would be clear that a vendor, rather than our own systems, was involved. Second, we wanted to emphasize that the effect on the business has been minimal. No costs have come up that would force us to state that we expect an effect on the business or a material one. And we aim to stay open regarding the path we're taking and to ensure we respond to whatever you ask.
I'd like to pose one more question regarding the cadence. I understand that, with respect to how the 45% and 55% are split, we remain on schedule. Regarding the EBITDA growth for the first half, which needs to pick up considerably during the back half, ought we to view that as mainly resulting from stronger growth, or perhaps from a better margin profile than what was posted in the year's first half? And then I have another question to ask.
Certainly. Yes. Well, a decent place to begin is simply what typically occurs on a sequential basis from Q1 right through Q4. As discussed on earlier calls, once deductibles reset, a sequential climb takes place, as you are aware. Thus, moving sequentially from Q1 into Q2, adjusted EBITDA for us rose by almost 11%. That illustrates what usually occurs given how seasonal this business is. Fairly significant step-ups appear purely because of seasonality; we therefore think this supports whatever takes place across every site annually, and it accounts for a large share of the picture. Beyond that, as Caitlin explained, an increasing portion of our volumes originates from advanced, and that as well delivers additional momentum on a sequential basis as the quarters progress. And naturally, with the de novos, we launched several near the close of 2024, and considerably more during 2025. Given how these typically ramp, they usually reach breakeven within roughly a year. So the ones launched during 2024 — only 4, versus greater than twice that figure, 10 — I mean, 9 in the prior year. Those are moving toward profitability during this year and already appear sooner within the numbers we report. There aren't a great many of them, yet those from '24 are precisely where we want them, which means they are generating some profit. The ones from 2025 will build considerably more momentum during the year's second half. Against our expectations, they are performing quite strongly. We lay out the timeline for when breakeven will be reached and where things proceed afterward. Not long ago we examined all of them closely and feel excellent regarding their direction. So that as well matters when it comes to sequential growth during the year's second half relative to what we posted in the first half.
Understood. All right, and to circle back to the policy — I really do appreciate that you addressed the suggested modifications regarding hospital reimbursement. When we consider what kinds of possibilities this might create for your company, how are we supposed to frame that? Is this merely a speeding up of the identical sort of expansion you've already witnessed with JV partnering chances? Or do you believe certain of these growth prospects might unfold in a way that differs from how they've played out previously for you?
Yeah. Thank you, Stephen; regarding the site neutrality proposed rule, we feel optimistic and enthusiastic. Of course, the outcome hinges on the final version. First, I believe — and this clarification matters — Lumexa does not depend on hospital outpatient reimbursement premiums; therefore, what's being proposed genuinely enhances how comparatively appealing our IDTF model is. My view is that this is a multiyear catalyst rather than something that will alter our results right away. What I believe it accomplishes is this: right now, it strengthens discussions already taking place about hospitals requiring additional imaging capacity, and constructing that capacity within an expensive hospital environment is growing harder and harder to defend. Then our model lets them broaden access, keep patients inside their network, take part economically, clearly, without depending on that hospital outpatient reimbursement premium. Thus we anticipate the initial effect will be greater urgency and more activity within our partnership pipeline, subsequently followed as time passes by additional centers and wider relationships; and I also wish to make clear that, obviously, our strategy isn't contingent on this rule getting finalized, but the — our fundamental value proposition already functions, though I do believe site neutrality would merely reinforce it.
So, looking at this quarter's operating cash flow, it seemed fairly strong. A lot of that, I believe, stemmed from a rise in accrued expenses. Could you discuss the cash flow situation in Q2, and what our expectations should be regarding operating cash flow and capital expenditures for the latter half of the year?
Absolutely. We're quite encouraged by what Q2 indicates for the guidance range we've set of 25% to 30% conversion rate. That equates to roughly $60 million to $70 million in free cash flow for the year. It's largely a matter of how things fall quarter by quarter. As you mentioned, working capital fluctuations are typical in this business. Those usually result in the second half outperforming the first. But occasionally, you get movements that benefit you and land in the same quarter. For Q2, that held true in our routine working capital, and the schedule of distributions from our JVs also helped. We received a few extra million from that; and honestly, both just occurred in Q2 instead of Q3. So we don't see the year any differently. Still, we clearly view Q2's results as showing why we set guidance at that 25% to 30% for the full year in the first place; and regarding your CapEx question, yes, we expect to spend $5 million to $7 million each quarter. I'd note we exceeded that in Q2 since we've been actively investing in growth opportunities; and we'll keep doing so wherever returns justify it. That might push us toward the upper end of the range. It wouldn't shock me if the annual figure ends up reflecting more of a $7 million per quarter pace later in the year, because if growth opportunities arise—whether launching additional de novos or other spending—we don't want to constrain ourselves to some arbitrary target, since we intend to grow and put that capital to work. With all that said, within the free cash flow guidance we've provided, we're very confident about it for the year.
All right. As a follow-up, I believe PET came up in the script. Could you remind us how many machines are in your centers? What share of revenues does PET represent nowadays? How should we view its role over the next 12 months? Are you gaining share from hospitals? And is the investment and share capture mostly happening at the JVs or at fully owned facilities?
Yes. We're really enthusiastic about PET's expansion; we've told you we have 8 PET machines, and our target was reaching 11 during this year. So 2 are already open and we're well on our way. Our focus has been that MRI and CT offer so much opportunity, and that's what the business prioritized throughout the year, though we do see meaningful growth potential in PET. We anticipate a substantial growth rate. The 23.2% we mentioned predated the 2 machines opening in July; so in Q3, expect that growth rate to keep climbing. Regarding where share is being taken — PET is among the most painful backlogs in many of the communities we enter, where we hear patients wait weeks, sometimes months, for PET exams. Consider what PET accomplishes: it aids diagnosis of often life-threatening illnesses and reveals whether treatment is working — whether treatment is halting disease progression — and waiting weeks and months is unacceptable. So we frequently enter markets with a major backlog, largely, of course, patients seen at hospitals unable to meet demand. Thus we expect continued growth both in our individual consolidated markets, which includes Arizona, where one of the additions occurred, and within our joint ventures, with the South Carolina site being a partnership with Atrium. So PET growth is exciting for the quarters ahead, certainly.
This is Matthew, filling in for Ryan Daniels. With advanced imaging at 37.4% of volume — a company record — I realize one of the company's objectives is to grow advanced imaging volume; but how should we consider the expansion of advanced imaging as a percentage of volume for the remainder of the year and perhaps into 2027 or over a longer horizon? And then, when I'm thinking, and when all of us are thinking, about what's driving advanced imaging, it sounds like it's simply a solid blend of industry trends and company initiatives. But does one carry more weight?
Thanks, Matt. I appreciate the question. Alright, so one thing we're really pleased about is that advanced made up 37.4% of all volume. That's an improvement of 111 basis points compared with Q2 2025, which is worth pointing out. We don't have a particular number we're aiming for. Growth is something we want across every area of the business. That said, when advanced outpaces routine, the revenue contribution is clearly meaningful — there's a 3x to 4x revenue premium attached to advanced, and that carries through to margin — so it's a major factor behind our growth and success. And if you think about what's behind the advance, well, you definitely have the secular forces at work: radiology, an aging population, more chronic conditions, and novel treatment paradigms. So demand is simply rising. We're taking every step possible to ensure we capture our fair share and expand faster than the industry does. That begins with the way we position our sales team. We've pointed out that we have more than 120 representatives out in the market, selling to our value proposition all day, every day. It also comes down to how we structure our operations so we keep adding capacity — for example, FastScan, where we remain on track to have 2/3 of our MRI fleet equipped with it, or virtual MRI, which we keep rolling out to help ensure that when a tech calls out, we can still run the machine. We're still keeping our attention squarely on capacity. Beyond that, we're being deliberate about picking locations for our fresh de novo facilities — each choice driven by regions where supply and demand don't line up, and where we can reach people who lack sufficient nearby options for advanced imaging. It's genuinely a thrill to operate in a sector enjoying such powerful tailwinds, and from both a sales and an operations standpoint, we're pulling out all the stops to set ourselves up for growth that outpaces the market.
When you consider how tight the labor market is for radiologists and techs overall, and given that you've been trying to use some of those technologies you brought up to boost capacity, is the online capacity you're seeing sufficient to fill the gap left by any capacity limits tied to labor? Or do these pressures mean some facilities end up with backlogs? I'm just wondering what capacity looked like in 2Q and how you're adjusting levels to keep up with demand.
Yeah, yeah. That's on our minds constantly. I'll take the first swing and put out a number or 2, and then Caitlin can broaden the picture on this. Sure, we view our expense here as being up 5% year-over-year. Our operating expenses going from '25 to '26. So against the inflationary backdrop we're generally seeing across the economy, that strikes us as fairly solid. And it's sort of — it has sort of been an inflationary line item for us. That said, there are definitely chances to make that better. And Caitlin, I know we put a lot of effort into retention and recruitment.
Yeah. Yeah. Yeah. So Ben, whenever you consider that 5%, it clearly takes in pre ramp-up costs tied to de novos. Therefore, if we set that against our revenue, expansion exists on top of it, plus chances are there that as revenue keeps climbing in tandem with the expenses, it's going to increase at a faster pace. And after that, what are we doing so we can keep on supporting. Clearly, I pointed to the Technologist Advancement Academy, and we keep on expanding our own pipeline. Being a setting where technologists enjoy working, as opposed to hospitals, gives us that edge. Plus we keep on deploying our virtual MRI solution, which lets a single tech operate several machines simultaneously, and that gives us greater capacity, particularly when we've got — we're hiring a tech, or someone calls out to look after their family <<inaudible>>; after that, on the radiologist side, this is exactly why we're fond of our 3-pronged model, more or less. There's Connexia, our telerad group, where we keep on recruiting and expanding the capacity inside that entity, our third-party radiologists whom we partner with across the markets we serve, and after that our affiliated physician groups. Consequently, with all of those combined, we can identify the proper solutions to back the ongoing growth.
Great. And as a follow-up, I'd like to take a moment to focus on Connexia. Given the wider remarks about industry demand and read turnaround times, could you update us on your thinking regarding that segment? I understand that partners are increasingly leaning into this area? Or perhaps it's resonating more strongly with potential partners?
Yes. Ben, frequently, when we talk with our health system partners, the fact that we're offering a rad read option to back the outpatient strategy is viewed as highly appealing and a point of differentiation in our approach. Some health systems definitely have a preference regarding rad read groups. So if that's the case, we'll back whatever suits the partnership best in the local market, but our ability to deliver additional capacity for our outpatient centers is definitely regarded as a plus during joint venture discussions.
Thanks. To wrap up, I'd like to express appreciation for the people on our team and the radiologists with us — their dedication to what we're trying to accomplish, and to the patients and communities we support, continues to be the bedrock of all that we do. Thanks for the questions you brought today. As we move into the back portion of 2026, we do so carrying real momentum, an expanding set of health system partners, and a great deal of belief in both our approach and how well our group can deliver on it. We're eager to share news about how things are going down the road. Enjoy your evening.
Appreciation goes out to everyone for joining us on this call today. That brings the program to a close. You're welcome to hang up at this point. Have a great day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Lumexa Imaging Holdings, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Lumexa Imaging Holdings, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.